)
Stryker (SYK) investor relations material
Stryker Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Strategy and financial framework
Strategy remains focused on performing at the high end of served markets; the three-year target remains 150 bps of adjusted operating margin expansion, with year-to-year cadence varying.
Free cash flow target remains 70%-80% each year; operational excellence and manufacturing efficiency are intended to support margin progress despite slower sales growth, particularly in 2026.
Margin initiatives include transferring production in-house, moving products to lower-cost sites in Warsaw and Mexico, optimizing the plant network, and streamlining support functions; improvement is expected to be generally steady through 2028, with larger gains during plant moves.
Leadership and operating model
Spencer Stiles is scheduled to become CEO in January 2027; priorities are accelerating growth, deepening specialization, and simplifying to scale through modernization and standardization.
Early leadership changes will focus on the operating model, with greater focus, discipline, and accountability; a potential third specialized group would cover areas such as Neurotechnology and vascular.
Operational opportunities include prioritizing best-cost facilities, scaling systems, and deploying AI across the broad plant network.
Cyber recovery and market conditions
Cyber disruption affected operations in 2026, including a multi-week shutdown; Inari supply softness is recovering, with stronger recent months and continued recovery expected through November and December.
Most cyber challenges are expected to be behind by 2027; 2027 quarterly comparisons will be uneven, so management recommends assessing growth on a full-year basis.
U.S. large-joint hip and knee market growth is estimated at 2.5%; economic pressure and insurance denials contributed to softness, with a gradual recovery expected as the economy strengthens and insurance resets take effect.
U.S. knee share gains continued in 2026, with growth at ~1.3x the market; Mako RPS and implant introductions are expected to build momentum, while a new hip impactor is planned for H2 2027.
Capital demand remained strong through the cyber event, with no order cancellations; near- and medium-term demand is expected to continue, though potential U.S. 340B effects on hospital finances are being monitored.
- Q2 sales plunged, but monthly trends improved as long-term growth targets remained intact.SYK
Q2 2020 - Sales rose 7.7% and adjusted EPS 10.3%; impairment weighed on reported earnings.SYK
Q3 2026 - Supply challenges persist in key segments, but strong capital demand and new products support growth.SYK
Wells Fargo 21st Annual Healthcare Conference - Q2 sales rose 9.4% and adjusted EPS climbed 17.9%, driven by strong recovery and volume growth.SYK
Q2 2026 - Full-year outlook remains strong, with robust recovery and innovation driving growth.SYK
Bank of America Global Healthcare Conference 2026 - Q3 net sales up 11.9% and adjusted EPS up 16.7%, with strong 2024 outlook.SYK
Q3 2024 - Growth driven by innovation, robotics, and portfolio shifts, with margin and global expansion in focus.SYK
Citi’s 2025 Medtech and Life Sciences Access Day - Raised 2025 outlook after double-digit organic growth and Inari acquisition, despite margin pressure.SYK
Q1 2025 - Double-digit organic growth, margin expansion, and strategic moves set up a strong 2025 outlook.SYK
Q4 2024
)
)
)
)
)
)
)
)